Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2021 | 468 | 0.910 |
Why?
|
| Oncologists | 4 | 2022 | 9 | 0.770 |
Why?
|
| Neoplasms | 8 | 2023 | 1667 | 0.510 |
Why?
|
| Cranial Irradiation | 2 | 2014 | 8 | 0.500 |
Why?
|
| Lung Neoplasms | 8 | 2018 | 1173 | 0.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2015 | 300 | 0.470 |
Why?
|
| Geriatric Assessment | 5 | 2022 | 107 | 0.460 |
Why?
|
| Chemoradiotherapy | 4 | 2018 | 54 | 0.430 |
Why?
|
| Radiation Injuries | 3 | 2018 | 97 | 0.400 |
Why?
|
| Prostatic Neoplasms | 6 | 2015 | 778 | 0.390 |
Why?
|
| Dacarbazine | 1 | 2010 | 32 | 0.370 |
Why?
|
| Aged | 35 | 2023 | 14862 | 0.360 |
Why?
|
| Quality of Life | 7 | 2021 | 1515 | 0.350 |
Why?
|
| Caregivers | 3 | 2021 | 365 | 0.300 |
Why?
|
| Melanoma | 1 | 2010 | 335 | 0.280 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 371 | 0.280 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 375 | 0.270 |
Why?
|
| Breast Neoplasms | 5 | 2016 | 1536 | 0.250 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 4848 | 0.250 |
Why?
|
| Middle Aged | 31 | 2019 | 21147 | 0.250 |
Why?
|
| Hot Flashes | 3 | 2010 | 8 | 0.240 |
Why?
|
| Humans | 43 | 2023 | 68618 | 0.210 |
Why?
|
| Medical Oncology | 2 | 2022 | 110 | 0.210 |
Why?
|
| Male | 30 | 2023 | 37321 | 0.210 |
Why?
|
| Vitamin E | 2 | 2015 | 55 | 0.200 |
Why?
|
| Treatment Outcome | 15 | 2021 | 7029 | 0.200 |
Why?
|
| Female | 31 | 2023 | 38074 | 0.200 |
Why?
|
| Abiraterone Acetate | 1 | 2021 | 2 | 0.190 |
Why?
|
| Survivors | 3 | 2015 | 256 | 0.190 |
Why?
|
| Academic Medical Centers | 2 | 2014 | 281 | 0.190 |
Why?
|
| Disease-Free Survival | 7 | 2021 | 349 | 0.190 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 33 | 0.190 |
Why?
|
| Health Education | 2 | 2014 | 279 | 0.180 |
Why?
|
| Patient Selection | 2 | 2016 | 592 | 0.180 |
Why?
|
| Double-Blind Method | 9 | 2018 | 1738 | 0.180 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2019 | 2 | 0.180 |
Why?
|
| Antioxidants | 2 | 2015 | 304 | 0.170 |
Why?
|
| Colonic Neoplasms | 2 | 2015 | 299 | 0.170 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 4 | 0.160 |
Why?
|
| Lisinopril | 1 | 2018 | 16 | 0.160 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2010 | 37 | 0.160 |
Why?
|
| Mometasone Furoate | 2 | 2016 | 2 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2019 | 215 | 0.150 |
Why?
|
| Diarrhea | 2 | 2016 | 63 | 0.150 |
Why?
|
| Carboplatin | 5 | 2015 | 59 | 0.150 |
Why?
|
| Selenomethionine | 2 | 2015 | 8 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 1070 | 0.140 |
Why?
|
| Carcinoma, Small Cell | 2 | 2007 | 53 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 261 | 0.140 |
Why?
|
| Surveys and Questionnaires | 5 | 2018 | 2800 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 446 | 0.140 |
Why?
|
| Sulfasalazine | 1 | 2016 | 3 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2008 | 99 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2015 | 714 | 0.140 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 235 | 0.140 |
Why?
|
| Pelvis | 1 | 2016 | 38 | 0.130 |
Why?
|
| Adult | 19 | 2021 | 21403 | 0.130 |
Why?
|
| Drug Administration Schedule | 4 | 2010 | 567 | 0.130 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 35 | 0.130 |
Why?
|
| Adenomatous Polyps | 1 | 2015 | 18 | 0.130 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 951 | 0.130 |
Why?
|
| Paclitaxel | 5 | 2015 | 140 | 0.130 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2015 | 42 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 561 | 0.130 |
Why?
|
| Boronic Acids | 2 | 2015 | 40 | 0.130 |
Why?
|
| Pyrazines | 2 | 2015 | 46 | 0.130 |
Why?
|
| Residence Characteristics | 2 | 2019 | 252 | 0.130 |
Why?
|
| Patient Care | 1 | 2015 | 61 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2015 | 63 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 285 | 0.120 |
Why?
|
| Medically Uninsured | 1 | 2015 | 99 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2015 | 141 | 0.120 |
Why?
|
| Doxepin | 1 | 2014 | 5 | 0.120 |
Why?
|
| Communication | 3 | 2022 | 329 | 0.120 |
Why?
|
| Stomatitis | 1 | 2014 | 8 | 0.120 |
Why?
|
| Facial Pain | 1 | 2014 | 8 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2016 | 146 | 0.120 |
Why?
|
| Administration, Oral | 3 | 2010 | 411 | 0.120 |
Why?
|
| Poverty | 1 | 2015 | 219 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 148 | 0.120 |
Why?
|
| Acute Pain | 1 | 2014 | 35 | 0.110 |
Why?
|
| Deoxycytidine | 4 | 2007 | 83 | 0.110 |
Why?
|
| Cataract Extraction | 1 | 2015 | 127 | 0.110 |
Why?
|
| Survival Rate | 5 | 2008 | 1056 | 0.110 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 378 | 0.110 |
Why?
|
| Cataract | 1 | 2015 | 134 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2015 | 311 | 0.110 |
Why?
|
| Community Networks | 1 | 2014 | 96 | 0.110 |
Why?
|
| Prognosis | 5 | 2021 | 2093 | 0.110 |
Why?
|
| Analgesics | 1 | 2014 | 118 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 848 | 0.100 |
Why?
|
| Camptothecin | 3 | 2007 | 39 | 0.100 |
Why?
|
| Neoplasm Staging | 6 | 2015 | 800 | 0.100 |
Why?
|
| Telephone | 2 | 2016 | 160 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 536 | 0.100 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2011 | 32 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 561 | 0.100 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2011 | 73 | 0.090 |
Why?
|
| Menopause | 2 | 2008 | 47 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2018 | 1342 | 0.090 |
Why?
|
| Pregnadienediols | 1 | 2010 | 1 | 0.090 |
Why?
|
| Radiodermatitis | 1 | 2010 | 8 | 0.090 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 125 | 0.090 |
Why?
|
| Amitriptyline | 1 | 2010 | 11 | 0.090 |
Why?
|
| Dermatologic Agents | 1 | 2010 | 32 | 0.090 |
Why?
|
| Baclofen | 1 | 2010 | 24 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 47 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 62 | 0.090 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2010 | 60 | 0.090 |
Why?
|
| Ketamine | 1 | 2010 | 57 | 0.080 |
Why?
|
| Amines | 1 | 2010 | 98 | 0.080 |
Why?
|
| Risk Factors | 5 | 2023 | 5731 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 581 | 0.080 |
Why?
|
| Decision Making | 1 | 2012 | 410 | 0.080 |
Why?
|
| Aging | 1 | 2015 | 911 | 0.080 |
Why?
|
| Selenium | 1 | 2008 | 36 | 0.080 |
Why?
|
| Megestrol Acetate | 1 | 2008 | 1 | 0.080 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 208 | 0.080 |
Why?
|
| Placebos | 3 | 2018 | 195 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 44 | 0.070 |
Why?
|
| Taxoids | 2 | 2007 | 41 | 0.070 |
Why?
|
| Libido | 1 | 2007 | 7 | 0.070 |
Why?
|
| Taste Disorders | 1 | 2007 | 3 | 0.070 |
Why?
|
| Organoplatinum Compounds | 1 | 2007 | 21 | 0.070 |
Why?
|
| Zinc Sulfate | 1 | 2007 | 4 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2021 | 7277 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 4 | 2008 | 41 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2018 | 86 | 0.070 |
Why?
|
| Testosterone | 1 | 2007 | 96 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 3259 | 0.070 |
Why?
|
| Thalidomide | 1 | 2006 | 24 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2021 | 138 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 74 | 0.070 |
Why?
|
| Cyclohexanols | 1 | 2006 | 12 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2006 | 9 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2008 | 332 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2005 | 41 | 0.060 |
Why?
|
| Counseling | 1 | 2007 | 280 | 0.060 |
Why?
|
| Anxiety | 2 | 2020 | 422 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2010 | 2358 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2010 | 2007 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2005 | 138 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 425 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2021 | 3705 | 0.060 |
Why?
|
| Focus Groups | 2 | 2016 | 247 | 0.060 |
Why?
|
| Depression | 2 | 2021 | 943 | 0.060 |
Why?
|
| Bortezomib | 2 | 2015 | 45 | 0.050 |
Why?
|
| South Carolina | 3 | 2015 | 2752 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 475 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 332 | 0.050 |
Why?
|
| Drug Combinations | 2 | 2015 | 304 | 0.050 |
Why?
|
| Acute Disease | 2 | 2016 | 658 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 319 | 0.050 |
Why?
|
| Prednisone | 1 | 2021 | 104 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1465 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2007 | 824 | 0.050 |
Why?
|
| Uncertainty | 1 | 2020 | 31 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 767 | 0.040 |
Why?
|
| Administration, Cutaneous | 2 | 2010 | 56 | 0.040 |
Why?
|
| Dyspnea | 1 | 2018 | 87 | 0.040 |
Why?
|
| Mental Health | 1 | 2020 | 278 | 0.040 |
Why?
|
| United States | 4 | 2015 | 7367 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 202 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 978 | 0.040 |
Why?
|
| Patient Safety | 1 | 2018 | 202 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 4655 | 0.030 |
Why?
|
| Enteritis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 75 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 32 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2015 | 108 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2015 | 44 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 729 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 114 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 82 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 117 | 0.030 |
Why?
|
| Mouthwashes | 1 | 2014 | 9 | 0.030 |
Why?
|
| Young Adult | 2 | 2015 | 5717 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2015 | 156 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1864 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2279 | 0.030 |
Why?
|
| Lung | 1 | 2018 | 849 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 238 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 371 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2016 | 403 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 260 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 340 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 733 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2015 | 287 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2014 | 328 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 792 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2015 | 326 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2011 | 45 | 0.020 |
Why?
|
| Prevalence | 1 | 2015 | 1619 | 0.020 |
Why?
|
| Pruritus | 1 | 2010 | 35 | 0.020 |
Why?
|
| Lecithins | 1 | 2010 | 1 | 0.020 |
Why?
|
| GABA-B Receptor Agonists | 1 | 2010 | 5 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1603 | 0.020 |
Why?
|
| Poloxamer | 1 | 2010 | 10 | 0.020 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2010 | 20 | 0.020 |
Why?
|
| Gels | 1 | 2010 | 55 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2010 | 128 | 0.020 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 5 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 8912 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 234 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 6 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2008 | 10 | 0.020 |
Why?
|
| Vidarabine | 1 | 2008 | 12 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 33 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2008 | 62 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 61 | 0.020 |
Why?
|
| Leucovorin | 1 | 2007 | 35 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 151 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 129 | 0.020 |
Why?
|
| Topotecan | 1 | 2006 | 17 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2007 | 82 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2007 | 130 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1054 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 100 | 0.020 |
Why?
|
| Neutropenia | 1 | 2006 | 72 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2006 | 242 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 245 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 334 | 0.020 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2006 | 42 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2007 | 392 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2007 | 183 | 0.020 |
Why?
|
| Nausea | 1 | 2005 | 47 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 369 | 0.020 |
Why?
|
| Vomiting | 1 | 2005 | 56 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 511 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 125 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 107 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 122 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2004 | 25 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 132 | 0.010 |
Why?
|
| Mediastinum | 1 | 2004 | 39 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 649 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2004 | 79 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 447 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 274 | 0.010 |
Why?
|
| Etoposide | 1 | 2003 | 64 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2004 | 258 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1745 | 0.010 |
Why?
|
| Cisplatin | 1 | 2003 | 192 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 1038 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 1615 | 0.010 |
Why?
|